Spago Nanomedical AB (OSTO:SPAGO) Stock Based Compensation: kr0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:SPAGO Spago Nanomedical AB OSTO:SPAGO
35 GF Score
Price kr0.11
GF Value kr0.03
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Spago Nanomedical AB Stock Based Compensation?

Spago Nanomedical AB OSTO:SPAGO -3.49% 35 Stock Based Compensation is kr0.00 Mil as of Mar. 2026. GuruFocus rates OSTO:SPAGO with a GF Score™ of 35/100 and a GF Value™ of kr0.03 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Spago Nanomedical AB's Stock Based Compensation for the three months ended in Mar. 2026 was kr0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.00 Mil.

Spago Nanomedical AB Stock Based Compensation Related Terms

Spago Nanomedical AB Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Spago Nanomedical AB's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spago Nanomedical AB Stock Based Compensation Chart

Spago Nanomedical AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Spago Nanomedical AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSTO:SPAGO
35GF Score
Spago Nanomedical AB OSTO:SPAGO
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Spago Nanomedical AB Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

What does a Stock Based Compensation of kr0.00 Mil mean?
Spago Nanomedical AB (OSTO:SPAGO) has a Stock Based Compensation of kr0.00 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Spago Nanomedical AB and its competitors.
Is Spago Nanomedical AB's Stock Based Compensation too high?
Spago Nanomedical AB's current Stock Based Compensation is kr0.00 Mil. Overall, Spago Nanomedical AB has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spago Nanomedical AB's Stock Based Compensation compare to VRTX and REGN?
Spago Nanomedical AB's Stock Based Compensation of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Spago Nanomedical AB and its competitors. Spago Nanomedical AB's current Stock Based Compensation is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spago Nanomedical AB stock overvalued right now?
Based on GuruFocus' analysis, Spago Nanomedical AB (OSTO:SPAGO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.03, compared to a current price of kr0.11 — trading 268.3% above its estimated fair value. The current Stock Based Compensation is kr0.00 Mil. Spago Nanomedical AB's overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Spago Nanomedical AB (OSTO:SPAGO), the current Stock Based Compensation is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Spago Nanomedical AB (OSTO:SPAGO) Overvalued in 2026?

Based on GuruFocus' analysis, Spago Nanomedical AB stock appears to be overvalued. The current stock price of kr0.11 is trading 268.3% above its estimated GF Value™ of kr0.03. GuruFocus considers Spago Nanomedical AB to be Significantly Overvalued.

Key valuation signals for OSTO:SPAGO:

  • Stock Based Compensation: kr0.00 Mil
  • GF Value™: kr0.03 vs. price of kr0.11 (268.3% above fair value)
  • GF Score™: 35/100 with 4 warning signs

No single metric tells the full story. See the OSTO:SPAGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Spago Nanomedical AB Business Description

Address Scheelevagen 22, Lund, SWE, SE-223 63
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through the previous detection of tumors and metastases. The Tumorad products focus on the development of a completely new form of radionuclide therapy for tumor-selective radiation therapy of cancer. The company's development projects are based on a platform of polymeric materials with various properties for the precise diagnosis and treatment of life-threatening and debilitating diseases.
35GF Score

Get the complete analysis for OSTO:SPAGO

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.11
Price
kr0.03
GF Value